TICKERNERD
Menu
NEONEOHealthcare · Diagnostics & Research

NEO Stock Forecast: NeoGenomics, Inc. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$20
+6.54% on the day

The 12 Wall Street analysts covering NeoGenomics, Inc. hold a median 12-month price target of $19 — -2.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 23 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$2.4B
Ticker Nerd rank
77 / 100
Median analyst target
$19
Analysts covering
12
Revenue$201.7M+11.2% y/y
Operating income−$9.8M
Net income$2.2M
Free cash flow$11.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.7%
1M
+19.2%
YTD
+66.3%
1Y
+148.5%
From 52W high
−1.8%
From 52W low
+172.0%
$7
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NEO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NeoGenomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Growth
84
Accruals
80
Revisions
76
Issuance
49
Quality
47
Volatility
46
Size
33
Value
32

Momentum (98): The shares have been drifting up relative to others.

Value (32): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NEO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NEO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26NEOHigh $35Median $19Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
8 Buy4 Hold0 Sell
Low $16Median $19High $35

The green dot is the last close — the median target sits −2.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 July 2026NeedhamMaintainsBuy$15 → $19
24 July 2026BenchmarkMaintainsBuy$11 → $16
29 Apr 2026BenchmarkUpgradeBuy—
29 Apr 2026BenchmarkUpgradeBuy$11
29 Apr 2026Leerink PartnersUpgradeOutperform$12 → $25
29 Apr 2026Leerink PartnersUpgradeOutperform—
29 Apr 2026TD CowenMaintainsBuy$13 → $14
29 Apr 2026TD CowenMaintainsBuy—
24 Feb 2026Piper SandlerMaintainsOverweight—
17 Feb 2026NeedhamMaintainsBuy—
12 Jan 2026NeedhamReiteratesBuy—
12 Sept 2025TD CowenMaintainsBuy—
2 Sept 2025Stephens & Co.MaintainsOverweight—
29 Aug 2025NeedhamMaintainsBuy—
4 Aug 2025Piper SandlerMaintainsOverweight—
30 July 2025Morgan StanleyMaintainsEqual-Weight—
29 July 2025NeedhamMaintainsBuy—
29 July 2025William BlairDowngradeMarket Perform—
6 May 2025Piper SandlerMaintainsOverweight—
1 May 2025Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NEO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NEO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, NeoGenomics, Inc. returned +148.5% against +17.4% for the S&P 500, dividends included.

NEO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26NEOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NEO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.1%
Analysts raising
4
Analysts cutting
2
Fundamentals

NeoGenomics, Inc. (NEO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−21.9×

Cheaper than 96% of US stocks

Price / sales
3.1×

Cheaper than 38% of US stocks

Price / book
3.0×

Cheaper than 31% of US stocks

EV / EBITDA
109.4×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
11.2%

Higher than 55% of US stocks

Earnings growth (YoY)
11.2%

Higher than 49% of US stocks

Gross margin
45.6%

Higher than 57% of US stocks

Operating margin
−4.8%

Higher than 27% of US stocks

Net margin
−6.8%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−6.3%

Higher than 38% of US stocks

Return on assets
−1.9%

Higher than 37% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NeoGenomics, Inc. (NEO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NeoGenomics, Inc. has a market value of $2.4B and an enterprise value of $2.7B.

  • Revenue in the twelve months to 30 June 2026: $766.3M. The latest quarter grew 11.2% year on year.

  • Net income over the same four quarters: −$51.9M, a −6.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.40.

  • Free cash flow in the twelve months to 30 June 2026: −$7.4M.

  • Shares outstanding: 127.9M.

  • Trailing P/E: −21.9×; forward P/E: 54.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • NeoGenomics, Inc. employs 2,500 people — $307K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

NEO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
NEONeoGenomics, Inc.$2.4B
77
WGSGeneDx Holdings Corp.$2.4B
46
CDNACareDx, Inc.$2.8B
99
FRNMFreenome, Inc.$1.7B
32
PSNLPersonalis, Inc.$1.7B
42
VCYTVeracyte, Inc.$3.5B
95
OPKOPKO Health, Inc.$1.3B
82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NeoGenomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NEO news & analysis

NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

MarketBeat · 21 Sept 2026positive

At the Morgan Stanley conference, NeoGenomics executives presented the company's strategy for expanding its role in community-based precision oncology. The plan centers on growth in next-generation sequencing, minimal residual disease testing, and workflow tools for physicians treating patients closer to home.

Why it matters — A NEO watcher would care because this outlines the company's growth focus areas in NGS, MRD testing, and community-based precision oncology.

NeoGenomics, Inc. (NEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

NeoGenomics, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item reports on the company's participation in the conference.

Why it matters — The presentation gives investors and NEO watchers direct insight into the company's strategy and outlook as communicated to the investment community.

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Business Wire · 1 Sept 2026neutral

NeoGenomics announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, scheduled for September 14–16, 2026, in New York.

Why it matters — Participation in a major healthcare conference gives NeoGenomics a platform to present to investors and industry peers, which NEO watchers may see as a routine opportunity for visibility.

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

Business Wire · 26 Aug 2026positive

NeoGenomics announced expanded Medicare MolDX coverage for its RaDaR ST minimal residual disease (MRD) assay, which is used for immunotherapy treatment response monitoring in late-stage solid tumors. The announcement was made via Business Wire from Fort Myers, Florida.

Why it matters — Expanded Medicare coverage for RaDaR ST could broaden access and adoption of NeoGenomics' MRD testing in immunotherapy monitoring for late-stage solid tumor patients.

Neo Performance Materials Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026positive

Neo Performance Materials (TSE: NEO) reported record second-quarter results, driven by higher volumes, favorable pricing and lower conversion costs across its business segments. The company reaffirmed its expectation to reach the high end of its increased 2026 adjusted EBITDA guidance.

Why it matters — The record quarterly results and reaffirmed upwardly revised 2026 adjusted EBITDA guidance signal sustained operational momentum across Neo Performance Materials' business segments.

FAQ

Frequently asked questions about NEO stock

What is the NEO stock price forecast for 2026-2027?

The 12 Wall Street analysts covering NeoGenomics, Inc. have a median 12-month price target of $19, with estimates ranging from $16 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NEO stock a buy right now?

Of the 12 analysts covering NeoGenomics, Inc., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeoGenomics, Inc. 77 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NEO?

As at 23 Sept 2026, NeoGenomics, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will NEO stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies -2.9% from the last close, and Ticker Nerd's factor model ranks NeoGenomics, Inc. 77 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NEO stock forecast for 2030?

No analyst covering NeoGenomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $35 over the next 12 months.

How has NEO stock performed over the past year?

NeoGenomics, Inc. returned +148.5% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NeoGenomics, Inc. do?

NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services.

What is the latest news on NEO?

The most recent item we track (MarketBeat, 21 Sept 2026): "NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference". At the Morgan Stanley conference, NeoGenomics executives presented the company's strategy for expanding its role in community-based precision oncology. The plan centers on growth in next-generation sequencing, minimal residual disease testing, and workflow tools for physicians treating patients closer to home.

Company

About NeoGenomics, Inc.

NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services. The company provides a broad menu of laboratory solutions across the cancer care continuum, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, and pathology support. Its services are used by oncologists, pathologists, hospitals, academic medical centers, and pharmaceutical companies to help characterize disease, guide treatment decisions, and support clinical research and drug development. NeoGenomics operates a network of cancer-focused laboratories in the United States and the United Kingdom, with business operations organized around Clinical Services and Advanced Diagnostics. Headquartered in Fort Myers, Florida, NeoGenomics plays a specialized role in precision medicine by delivering laboratory data and expert interpretation for cancer diagnosis and care.

CEO Mr. Anthony P. Zook · 2,500 employees · United States · https://www.neogenomics.com